Clinical Trials Directory

Trials / Completed

CompletedNCT00561821

Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)

A Double-Blind, Randomized, Parallel Group, Placebo- Controlled Sleep Laboratory Efficacy and Safety Study With Org 50081 in Elderly Subjects With Chronic Primary Insomnia

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
538 (actual)
Sponsor
Merck Sharp & Dohme LLC · Industry
Sex
All
Age
65 Years
Healthy volunteers
Not accepted

Summary

This study was conducted to investigate the efficacy of treatment with Org 50081 (Esmirtazapine) compared to placebo in elderly participants with chronic primary insomnia. Primary efficacy variable is Wake time After Sleep Onset (WASO), averaged over all in-treatment time points and measured by polysomnography (PSG).

Detailed description

Insomnia is a common complaint or disorder throughout the world. About one third of the population in the industrial countries reports difficulty initiating or maintaining sleep, resulting in a non-refreshing or non-restorative sleep. The majority of the insomniacs suffer chronically from their complaints. The maleic acid salt of Org 4420, code name Org 50081, known as Esmirtazapine, was selected for development in the treatment of insomnia. The first clinical trial with Esmirtazapine was a proof-of-concept trial with a four-way cross-over design. All 3 Esmirtazapine dose groups showed a statistically significant positive effect on TST (objective and subjective) and WASO, as compared to placebo. The current study is designed to assess the efficacy and safety of Esmirtazapine in a double-blind, placebo-controlled, parallel, randomized trial in elderly participants suffering from chronic primary insomnia.

Conditions

Interventions

TypeNameDescription
DRUGEsmirtazapineone tablet daily
DRUGPlaceboone tablet daily

Timeline

Start date
2007-11-20
Primary completion
2009-12-21
Completion
2009-12-21
First posted
2007-11-21
Last updated
2018-10-03
Results posted
2014-08-05

Source: ClinicalTrials.gov record NCT00561821. Inclusion in this directory is not an endorsement.